Biologic agents have been proven to be highly effective in treating inflammatory diseases such as rheumatoid arthritis (RA), adult ulcerative colitis (UC), psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and adult and pediatric Crohn’s disease (CD). Unfortunately, many health care plans restrict the use of these agents due to high cost.

Biosimilars are biopharmaceuticals that have been genetically engineered to be highly similar – meaning any difference is minor and not clinically meaningful – to an already existing approved biologic product.  While biosimilars have been available in Europe since 2005, the first biosimilar monoclonal antibody in the United States, infliximab, has recently been approved for use in treating an array of inflammatory diseases.

Tune into these NEW CMEO Snacks today, featuring expert faculty, and join Dr. Leonard Calabrese on Wednesday, September 20th at NOON for a LIVE Q&A to further discuss the interchangeability, efficacy, and safety of biosimilars in the treatment of ID!

Get started on these 15-minute activities now

An Evolving Treatment Landscape for Inflammatory Disease: Involving Patients in the Discussion of Biosimilars

Click here to get started!


An Evolving Treatment Landscape for Inflammatory Disease: The Role of Biosimilars in RA and IBD

Click here to get started!

Register today for the LIVE Q&A with Dr. Calabrese

Debating Interchangeability, Efficacy, and Safety of Biosimilars in the Management of Inflammatory Diseases 

Date: September 20, 2017

Time: 12:00p – 12:30p ET

Click here to sign up for free! 


Russell D. Cohen, MD, FACG, AGAF



Edward Li, PharmD, MPH, BCOP



Leonard H. Calabrese, DO

Download these free resources for use in your own practice with your patients!